Niagen Bioscience, Inc. 8-K

What Happened

• On March 19, 2026, Niagen Bioscience, Inc. (NAGE) announced that its Board of Directors approved an increase in the company's share repurchase authorization from $10.0 million to $20.0 million. The company noted it has repurchased approximately $2.6 million of common stock under the program through March 17, 2026.
• The repurchase program allows purchases in the open market, through negotiated transactions or pursuant to Rule 10b5-1 plans, and may be conducted in accordance with Rule 10b-18. The program is expected to remain in effect for the previously approved 24-month period unless earlier changed or terminated by the Board.

Key Details

• New authorization: up to $20.0 million of common stock (previously $10.0 million).
• Repurchases to date: approximately $2.6 million through March 17, 2026.
• Original program approval date: October 31, 2025 (previous $10.0M authorization).
• Repurchases subject to market conditions, securities laws, and Board discretion; program may be suspended or discontinued at any time.

Why It Matters

• A larger buyback authorization gives the company more flexibility to return capital to shareholders and to repurchase shares when management views the stock as attractively priced.
• For investors, buybacks can reduce share count over time and potentially support per-share metrics, but the program does not obligate Niagen Bioscience to repurchase any specific amount and can be changed or halted by the Board.